Phase 3 Ankylosing Spondylitis Trial, Recruiting (NCT07237568)

Phase 3 Ankylosing Spondylitis Trial, Recruiting NCT07237568 Sponsor: Lynk Pharmaceuticals Co., Ltd Condition: Ankylosing Spondylitis

Printed from Voxsanity (voxsanity.com.au) — NCT07237568 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Ankylosing Spondylitis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed by a doctor with ankylosing spondylitis (a type of inflammatory arthritis affecting the spine) and meet a specific set of standard diagnostic criteria for this condition.
Your disease activity and back pain have been measured using standard scoring tools at two separate appointments, with both scores rated at 4 or higher out of 10, showing your condition is significantly active.
You have tried at least 2 anti-inflammatory pain medications (such as ibuprofen or naproxen) at the highest recommended or tolerated doses for at least 4 weeks in total without enough benefit, or you are unable to take these types of medications due to intolerance or another medical reason.

Who may not be able to join:

Your spine has become completely fused (fully locked/stiffened along its entire length).
You have a known allergy to any ingredient in the study medication.
You currently need to take certain medications that are not allowed during this trial (confirm with trial site).
You are currently pregnant, breastfeeding, or planning to become pregnant during the time the trial is running.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 13501069845

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07237568

Sponsor: Lynk Pharmaceuticals Co., Ltd

Phase: Phase 3

Status: Recruiting

Condition: Ankylosing Spondylitis

Trial contact: 13501069845

More information: https://clinicaltrials.gov/study/NCT07237568

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed by a doctor with ankylosing spondylitis (a type of inflammatory arthritis affecting the spine) and meet a specific set of standard diagnostic criteria for this condition.
Your disease activity and back pain have been measured using standard scoring tools at two separate appointments, with both scores rated at 4 or higher out of 10, showing your condition is significantly active.
You have tried at least 2 anti-inflammatory pain medications (such as ibuprofen or naproxen) at the highest recommended or tolerated doses for at least 4 weeks in total without enough benefit, or you are unable to take these types of medications due to intolerance or another medical reason.

Who may not be able to join:

Your spine has become completely fused (fully locked/stiffened along its entire length).
You have a known allergy to any ingredient in the study medication.
You currently need to take certain medications that are not allowed during this trial (confirm with trial site).
You are currently pregnant, breastfeeding, or planning to become pregnant during the time the trial is running.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 3

Sponsor

Lynk Pharmaceuticals Co., Ltd

Registry

ClinicalTrials.gov

Start date

29 August 2025

Est. completion

1 November 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Percentage of Participants Achieving Assessment of SpondyloArthritis International Society 40 (ASAS40) Response at Week 16

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov